LadRx Corporation

$0.05-50.00%($-0.05)
TickerSpark Score
46/100
Weak
95
Valuation
55
Profitability
15
Growth
36
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LADX research report →

52-Week Range2% of range
Low $0.01
Current $0.05
High $2.40

Companywww.cytrx.com

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022.

CEO
John Y. Caloz
IPO
1989
Employees
2
HQ
Los Angeles, CA, US

Price Chart

-96.86% · this period
$2.15$1.08$0.00May 19Nov 17May 19

Valuation

Market Cap
$24.75K
P/E
-0.06
P/S
3.58
P/B
-0.01
EV/EBITDA
0.13
Div Yield
0.00%

Profitability

Gross Margin
40.77%
Op Margin
-20061.01%
Net Margin
-5607.96%
ROE
21.84%
ROIC
65.05%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-1,589,685,000 · -397081.59%
EPS
$-3210.89 · -472289.71%
Op Income
$-3,623,142
FCF YoY
-129337.93%

Performance & Tape

52W High
$2.40
52W Low
$0.01
50D MA
$0.08
200D MA
$0.90
Beta
1.56
Avg Volume
113

Get TickerSpark's AI analysis on LADX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jan 15, 24Caldwell Joel Kother5,000
Jan 15, 24Claiborne Cary Jother5,000
Jan 15, 24Simpson Jennifer K.other5,000
Jan 15, 24CALOZ JOHN Yother15,000
Jan 15, 24Snowdy Stephenother25,000

Our LADX Coverage

We haven't published any research on LADX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate LADX Report →

Similar Companies